Literature DB >> 20676840

Noninvasive assessment of acute cardiopulmonary effects of an oral single dose of sildenafil in patients with idiopathic pulmonary hypertension.

Neda Behzadnia1, Katayoun Najafizadeh, Babak Sharif-Kashani, Davoud Oulad Dameshghi, Payman Shahabi.   

Abstract

We aimed to assess the acute cardiopulmonary effects of a 100-mg oral single dose of sildenafil in patients with idiopathic pulmonary hypertension (IPAH) using a well-validated but less-used noninvasive echocardiographic method for the measurement of both systolic and diastolic pulmonary artery pressure (PAP), by tricuspid regurgitation (TR) velocity curve analysis. We studied 12 consecutive patients with IPAH (10 patients with New York Heart Association functional class III, and 2 patients with functional class II). A 100-mg oral single dose of sildenafil was added to previous medications of all patients and its immediate effects were evaluated 1, 5, and 12 h after treatment. Using paired analysis, administration of a 100-mg oral single dose of sildenafil led to a significant reduction in mean PAP and a remarkable increase in pulmonary acceleration time (PAT) 1 h after treatment (P = 0.000; 95% confidence interval [CI] 18.99-26.00 and P = 0.005; 95% CI -12.89 to -2.95, respectively). In addition, although the right heart dimensions (right atrium and right ventricle) showed a trend toward improvement, the differences were not statistically significant (P = 0.13 and P = 0.08, respectively). Our results demonstrated that Doppler examination of TR alone can be easily used for the estimate of systolic and diastolic PAP in patients with IPAH. This study also shows that sildenafil is the only drug given orally that can evaluate the vasodilatory capacity of the pulmonary vascular bed in patients with IPAH, with promising effects on mPAP and PAT in these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20676840     DOI: 10.1007/s00380-009-1208-4

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  34 in total

Review 1.  Cyclic GMP phosphodiesterase-5: target of sildenafil.

Authors:  J D Corbin; S H Francis
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

2.  Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava.

Authors:  B J Kircher; R B Himelman; N B Schiller
Journal:  Am J Cardiol       Date:  1990-08-15       Impact factor: 2.778

3.  A concordance correlation coefficient to evaluate reproducibility.

Authors:  L I Lin
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

4.  Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure.

Authors:  K L Chan; P J Currie; J B Seward; D J Hagler; D D Mair; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1987-03       Impact factor: 24.094

5.  Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients.

Authors:  P J Currie; J B Seward; K L Chan; D A Fyfe; D J Hagler; D D Mair; G S Reeder; R A Nishimura; A J Tajik
Journal:  J Am Coll Cardiol       Date:  1985-10       Impact factor: 24.094

6.  Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells.

Authors:  Benedetta Tantini; Alessandra Manes; Emanuela Fiumana; Carla Pignatti; Carlo Guarnieri; Romano Zannoli; Angelo Branzi; Nazzareno Galié
Journal:  Basic Res Cardiol       Date:  2004-11-24       Impact factor: 17.165

7.  Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Authors:  Michael McGoon; David Gutterman; Virginia Steen; Robin Barst; Douglas C McCrory; Terry A Fortin; James E Loyd
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

8.  Measurement of pulmonary artery diastolic pressure from the right ventricle.

Authors:  D W Reynolds; N Bartelt; R Taepke; T D Bennett
Journal:  J Am Coll Cardiol       Date:  1995-04       Impact factor: 24.094

9.  Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy.

Authors:  Sundeep Bhatia; Robert P Frantz; Cathy J Severson; Louise A Durst; Michael D McGoon
Journal:  Mayo Clin Proc       Date:  2003-10       Impact factor: 7.616

10.  Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH).

Authors:  J Suntharalingam; R J Hughes; K Goldsmith; N Doughty; P George; M Toshner; K K Sheares; J Pepke-Zaba
Journal:  Vascul Pharmacol       Date:  2007-02-12       Impact factor: 5.773

View more
  5 in total

1.  Monocrotaline-induced pulmonary hypertension with sufficient tricuspid regurgitation in a rat model.

Authors:  Fuminobu Ishikura; Ryoko Azakami; Toshihiko Asanuma; Shintaro Beppu
Journal:  J Med Ultrason (2001)       Date:  2012-05-24       Impact factor: 1.314

2.  Mechanisms of exercise-induced pulmonary hypertension in patients with cardiac septal defects.

Authors:  Henrik Brun; Thomas Moller; Per M Fredriksen; Erik Thaulow; Are H Pripp; Henrik Holmstrom
Journal:  Pediatr Cardiol       Date:  2012-03-01       Impact factor: 1.655

Review 3.  Reversible course of pulmonary arterial hypertension related to bone marrow transplantation.

Authors:  Alisa Limsuwan; Samart Pakakasama; Suradej Hongeng
Journal:  Heart Vessels       Date:  2011-01-07       Impact factor: 2.037

4.  Natural and unnatural history of tetralogy of Fallot repaired during adolescence and adulthood.

Authors:  Ming-Chun Yang; Shuenn-Nan Chiu; Jou-Kou Wang; Chun-Wei Lu; Ming-Tai Lin; Chun-An Chen; Chung-I Chang; Yih-Sharng Chen; Ing-Sh Chiu; Mei-Hwan Wu
Journal:  Heart Vessels       Date:  2011-02-18       Impact factor: 2.037

5.  Comparison of preventive effect of sildenafil and therapeutic effect of sildenafil treatment in rats with monocrotaline-induced pulmonary arterial hypertension.

Authors:  Rieko Yoshiyuki; Ryuji Fukushima; Ryo Tanaka; Noboru Machida
Journal:  J Vet Med Sci       Date:  2016-06-17       Impact factor: 1.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.